Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,203 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07110454Recruiting
Long-term follow-up study for epilepsy monitoring implant
This study follows people who previously enrolled in the DETECT study and had a Minder device implanted to monitor brain activity. The goal is to see how the device performs over a longer period of time.
Phoenix, ArizonaAges 18–75 - NCT02966756RecruitingPhase 2
Venetoclax for relapsed or resistant CLL/SLL after prior treatment
This trial studies venetoclax, a targeted medicine, for people with CLL or SLL that has come back or did not respond to prior therapy. It’s likely for patients who still need treatment and have specific genetic or treatment-history features.
Concord, New South WalesAges 18 years+ - NCT03050190RecruitingPhase 1/Phase 2
Study of CD19 CAR T-like cells for hard-to-treat B cancers
This trial tests lab-made immune cells (called 4SCAR19) that are designed to find and attack CD19-positive B-cell cancers that have come back or did not respond to treatment. You may be considered if you meet age, blood test, infection, pregnancy, and general health requirements.
Shenzhen, GuangdongAges 6 months+ - NCT03099356RecruitingPhase 2
Cyclophosphamide and sirolimus for thyroid cancer that won’t respond to iodine
This trial tests whether the combination of cyclophosphamide and sirolimus can slow or shrink metastatic thyroid cancer that does not respond to iodine-131. It may help people whose cancer can’t be cured with surgery or other standard options and is still growing.
Ann Arbor, MichiganAges 18 years+ - NCT03266640RecruitingPhase 2
CMV cell therapy for difficult-to-treat viral infection
This trial tests an immune cell treatment (CMV-specific cytotoxic T cells) for people with a CMV infection that is not improving despite standard antivirals, or who cannot tolerate them. If eligible, the treatment aims to help the body control the virus after transplant-related immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT03266627RecruitingPhase 2
Adenovirus T-cell therapy for hard-to-treat virus after transplants
This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.
Los Angeles, CaliforniaAges 1 month–79 years - NCT03266653RecruitingPhase 2
T-cell therapy for stubborn Epstein-Barr virus after transplants
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Los Angeles, CaliforniaAges 1 month–79 years - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Baltimore, MarylandAges 12 years+ - NCT03459534RecruitingPhase 3
Radotinib for CML patients after prior TKI failure
This trial tests radotinib (a targeted pill) in people with chronic-phase Philadelphia chromosome–positive CML whose previous TKIs stopped working or could not be tolerated. It aims to improve control of the leukemia while checking safety.
BarnaulAges 18 years+ - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT03494296Recruiting
Low-dose decitabine plus COP for relapsed lymphoma
This trial studies whether a low-dose chemotherapy medicine (decitabine) combined with a COP chemotherapy regimen can help adults whose diffuse large B-cell lymphoma (DLBCL) has come back or did not respond to treatment. It may be an option if you have measurable disease and can meet key safety and health requirements.
Harbin, HeilongjiangAges 18 years+ - NCT03631953RecruitingPhase 1
Test alpelisib plus trametinib for hard-to-treat meningiomas
This Phase 1 trial studies whether combining two targeted medicines—alpelisib and trametinib—can shrink or slow progressive meningiomas that have already been treated with standard surgery and radiation. If you qualify, you may help test a new treatment approach for tumors that keep growing.
MarseilleAges 18 years+ - NCT03644732Recruiting
Study of brain activity during epilepsy testing using SEEG
This study maps how thinking and memory work by recording brain signals during a presurgical epilepsy workup. It may help doctors better understand drug-resistant focal epilepsy and improve how they plan treatment.
GrenobleAges 18–65 - NCT03647852Recruiting
Study for difficult IgA vasculitis with gut symptoms
This study looks at treatment strategies for children with IgA vasculitis (also called Henoch-Schönlein purpura) when it mainly affects the stomach and intestines and symptoms do not improve with standard steroid dosing. It may help find better ways to control the illness early and prevent serious complications.
ShanghaiAges 2–16 - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+ - NCT03681561RecruitingPhase 1/Phase 2
Nivolumab plus ruxolitinib for relapsed Hodgkin lymphoma
This trial tests nivolumab (an immune therapy) combined with ruxolitinib (a drug that targets immune signaling) for people whose classical Hodgkin lymphoma has come back or did not respond. It may help shrink the lymphoma and improve disease control after prior treatments, including checkpoint inhibitor therapy.
Chicago, IllinoisAges 18 years+ - NCT03738072Recruiting
Test of brain electrical stimulation to plan epilepsy surgery
This study looks at how using a mild electrical stimulation in the brain may help doctors plan surgery for people with drug-resistant focal (partial) epilepsy. It happens during a hospital procedure to map the seizure areas (SEEG), so it may help improve where surgery targets.
ToulouseAges 12–65 - NCT03761108RecruitingPhase 1/Phase 2
Study of linvoseltamab for hard-to-treat multiple myeloma
This trial tests linvoseltamab, an experimental antibody medicine, in adults whose multiple myeloma has come back or does not respond to treatment. It may help some people by targeting myeloma cells after multiple prior therapies have failed.
Miami, FloridaAges 18 years+ - NCT03826992RecruitingPhase 1
Study drug Venetoclax plus Vyxeos for hard-to-treat leukemia
This Phase 1 study tests whether a combination of venetoclax and Vyxeos can treat children and young adults with certain relapsed or treatment-resistant acute leukemias. It may help shrink the leukemia or improve blood counts when standard treatments have not worked.
Cincinnati, OhioAges 1–39 - NCT03838042RecruitingPhase 1/Phase 2
Testing nivolumab plus entinostat for high-risk childhood cancers
This trial studies whether nivolumab (an immune therapy) plus entinostat (an epigenetic medicine) can help children and teens with high-risk cancers that have come back, worsened, or did not respond to prior treatment. It also looks at specific tumor “biomarkers” to group patients and guide how the study is run.
Randwick, New South WalesAges 2–21 - NCT03895593Recruiting
Fecal transplant for stubborn intestinal infections
This study looks at “rescue” fecal microbiota transplantation (FMT), which replaces gut microbes using stool from a screened donor, for intestinal infections that have not improved with standard care. It may help patients whose infection keeps coming back or doesn’t respond to treatment.
Nanjing, JiangsuAges Any age - NCT03936153RecruitingPhase 2
Oral abexinostat for relapsed lymphoma after two prior treatments
This Phase 2 study tests how well and how safely an oral medicine called abexinostat works for people with diffuse large B-cell lymphoma that has come back or did not respond to the last treatment. It may help by shrinking lymphoma and controlling the disease using a medication taken by mouth.
BeijingAges 18 years+ - NCT03937544RecruitingPhase 2/Phase 3
Study of your own CAR-T cells for hard-to-treat B-ALL
This trial tests a treatment made from your own immune cells (CAR-T cells) to help control relapsed or refractory B-ALL. It is designed for people whose disease has come back or not responded to prior therapy, and who have specific brain/spinal fluid and organ health requirements.
Bandar Tun Razak, Kuala LumpurAges 13–65 - NCT03944876RecruitingPhase 3
Botulinum toxin to block a facial nerve for chronic cluster headaches
This trial tests whether injections of botulinum toxin type A can reduce frequent, severe cluster headache attacks by targeting a facial nerve area. It’s for people whose cluster headaches have not responded well—or have caused side effects—to standard preventive treatments.
HamburgAges 18–85
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,203 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.